Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Holly E. Barker"'
Autor:
Ksenija Nesic, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya Kwan, Elizabeth Lieschke, Gwo-Yaw Ho, Holly E. Barker, Justin Bedo, Silvia Casadei, Andrew Farrell, Marc Radke, Kristy Shield-Artin, Jocelyn S. Penington, Franziska Geissler, Elizabeth Kyran, Robert Betsch, Lijun Xu, Fan Zhang, Alexander Dobrovic, Inger Olesen, Rebecca Kristeleit, Amit Oza, Iain McNeish, Gayanie Ratnayake, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D. L. Bowtell, Thomas C. Harding, Kevin Lin, Elizabeth M. Swisher, Olga Kondrashova, Clare L. Scott, Neil Johnson, Matthew J. Wakefield
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Mul
Externí odkaz:
https://doaj.org/article/8f0a9b712db94dd79db01d43d570add9
Autor:
Haineng Xu, Sarah B. Gitto, Gwo-Yaw Ho, Sergey Medvedev, Kristy Shield-Artin, Hyoung Kim, Sally Beard, Yasuto Kinose, Xiaolei Wang, Holly E. Barker, Gayanie Ratnayake, Wei-Ting Hwang, Ryan J. Hansen, Bryan Strouse, Snezana Milutinovic, Christian Hassig, Matthew J. Wakefield, Cassandra J. Vandenberg, Clare L. Scott, Fiona Simpkins
Publikováno v:
iScience, Vol 27, Iss 7, Pp 109978- (2024)
Summary: High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC with CCNE1 amplification (CCNE1am
Externí odkaz:
https://doaj.org/article/1ed5cdda17844d2e8fc282a3b801056b
Autor:
Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-20 (2023)
Abstract Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous
Externí odkaz:
https://doaj.org/article/90697e9e0fe04ca583a35a4167337ba8
Autor:
Gwo Yaw Ho, Cassandra J. Vandenberg, Ratana Lim, Elizabeth L. Christie, Dale W. Garsed, Elizabeth Lieschke, Ksenija Nesic, Olga Kondrashova, Gayanie Ratnayake, Marc Radke, Jocelyn S. Penington, Amandine Carmagnac, Valerie Heong, Elizabeth L. Kyran, Fan Zhang, Nadia Traficante, Ruby Huang, Alexander Dobrovic, Elizabeth M. Swisher, Orla McNally, Damien Kee, Matthew J. Wakefield, Anthony T. Papenfuss, David D. L. Bowtell, Holly E. Barker, Clare L. Scott
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinu
Externí odkaz:
https://doaj.org/article/acfd52763fdb4a6092abd9806478e071
Autor:
Arwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, Melvin Wong, Martin Weltman, Ratana Lim, Christopher McEvoy, Andrew Fellowes, Stephen Fox, Justin Bedő, Jocelyn Penington, Kym Pham, Oliver Hofmann, Joseph H. A. Vissers, Sean Grimmond, Gayanie Ratnayake, Michael Christie, Catherine Mitchell, William K. Murray, Kelly McClymont, Peter Luk, Anthony T. Papenfuss, Damien Kee, Clare L. Scott, David Goldstein, Holly E. Barker
Publikováno v:
Cancers, Vol 15, Iss 17, p 4378 (2023)
Background: Epithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a WWTR1::CAMTA1 gene fusion in approximately 90% of cases, or a YAP1::TF
Externí odkaz:
https://doaj.org/article/7d882a5d692049d69e1d2be66018fcfe
Autor:
Hind Hafsi, Magnus T. Dillon, Holly E. Barker, Joan N. Kyula, Ulrike Schick, James T. Paget, Henry G. Smith, Malin Pedersen, Martin McLaughlin, Kevin J. Harrington
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer deaths. Cisplatin-based chemoradiotherapy is a standard of care for locally advanced disease. ATR and DNA-PK inhibition (DNA-PKi) are actively being investigated in clinic
Externí odkaz:
https://doaj.org/article/3c303a60120b478795c17ff33f334ec1
Autor:
Gwo Yaw, Ho, Elizabeth L, Kyran, Justin, Bedo, Matthew J, Wakefield, Darren P, Ennis, Hasan B, Mirza, Cassandra J, Vandenberg, Elizabeth, Lieschke, Andrew, Farrell, Anthony, Hadla, Ratana, Lim, Genevieve, Dall, James E, Vince, Ngee Kiat, Chua, Olga, Kondrashova, Rosanna, Upstill-Goddard, Ulla-Maja, Bailey, Suzanne, Dowson, Patricia, Roxburgh, Rosalind M, Glasspool, Gareth, Bryson, Andrew V, Biankin, Susanna L, Cooke, Gayanie, Ratnayake, Orla, McNally, Nadia, Traficante, Anna, DeFazio, S John, Weroha, David D, Bowtell, Iain A, McNeish, Anthony T, Papenfuss, Clare L, Scott, Holly E, Barker
Publikováno v:
Cancer Research. 82:4457-4473
Ovarian carcinosarcoma (OCS) is an aggressive and rare tumor type with limited treatment options. OCS is hypothesized to develop via the combination theory, with a single progenitor resulting in carcinomatous and sarcomatous components, or alternativ
PDF file - 911K, S2: Inhibition of LOXL2 in 4T1 CM reduces fibroblast branching on collagen and collagen contraction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b14e15dbac0e1f329758d67a0f44450a
https://doi.org/10.1158/1541-7786.22510128
https://doi.org/10.1158/1541-7786.22510128
Autor:
Kevin J. Harrington, Martin McLaughlin, Christopher M. Nutting, Kate L. Newbold, Shreerang A. Bhide, Hind Hafsi, Malin Pedersen, Holly E. Barker, Magnus T. Dillon
Supplementary figures 1-4, supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d33e773df37337cb3f3754278872ff2
https://doi.org/10.1158/1535-7163.22508769.v1
https://doi.org/10.1158/1535-7163.22508769.v1
Cancer-associated fibroblasts enhance cancer progression when activated by tumor cells through mechanisms not yet fully understood. Blocking mammary tumor cell–derived lysyl oxidase-like 2 (LOXL2) significantly inhibited mammary tumor cell invasion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5411db0de9738aa5d47fa2a52c84b5fc
https://doi.org/10.1158/1541-7786.c.6539517.v1
https://doi.org/10.1158/1541-7786.c.6539517.v1